title: Antifungal prophylaxis in haematology patients: the role of voriconazole.
abstract: Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in haematopoietic stem cell transplant (HCT) recipients and patients with haematological malignancies. Early treatment initiation is vital for improving survival, but is hampered by difficulties in timely diagnosis. Prophylaxis with a broad-spectrum antifungal, such as voriconazole, has the potential to decrease the incidence of IFI in haematology patients. Based on a growing body of data, voriconazole appears to be effective for the primary and secondary prevention of IFIs in HCT recipients, with generally good tolerability.
authors.affiliation: Service d'Hématologie Clinique, Assistance Publique-Hopitaux de Paris, Hôpital Henri Mondor, University Paris Est-Créteil, 51 Av. Maréchal de Lattre de Tassigny, Créteil, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Hicheri
authors.forename: G
authors.initials: G
authors.lastname: Cook
authors.forename: C
authors.initials: C
authors.lastname: Cordonnier
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000517:prevention & control*; D001230:Aspergillus / Q000302:isolation & purification*; D002986:Clinical Trials as Topic; D019337:Hematologic Neoplasms / Q000382:microbiology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D011743:Pyrimidines / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole